208 related articles for article (PubMed ID: 1824955)
1. Pituitary and brain D2 receptor density measured in vitro and in vivo in EEDQ treated male rats.
Ekman A; Eriksson E
Life Sci; 1991; 48(4):321-31. PubMed ID: 1824955
[TBL] [Abstract][Full Text] [Related]
2. A high dose of EEDQ reduces pituitary dopamine D2 receptor density and the prolactin suppressive potency of agonists.
Ekman A; Eriksson E
Eur J Pharmacol; 1993 Oct; 243(3):295-9. PubMed ID: 7903944
[TBL] [Abstract][Full Text] [Related]
3. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
Giorgi O; Biggio G
Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234
[TBL] [Abstract][Full Text] [Related]
4. Effects of the two partial D2 agonists (+)- and (-)-3-PPP on prolactin release in EEDQ treated male rats.
Ekman A; Quiding M; Eriksson E
Life Sci; 1991; 48(4):311-20. PubMed ID: 1671291
[TBL] [Abstract][Full Text] [Related]
5. Dopamine receptor reappearance after irreversible receptor blockade: effect of chronic estradiol treatment of ovariectomized rats.
Lévesque D; Di Paolo T
Mol Pharmacol; 1991 May; 39(5):659-65. PubMed ID: 1674586
[TBL] [Abstract][Full Text] [Related]
6. The dopamine D2 antagonist remoxipride acts in vivo on a subpopulation of dopamine D2 receptors.
Ogren SO; Rosén L; Fuxe K
Neuroscience; 1994 Jul; 61(2):269-83. PubMed ID: 7969908
[TBL] [Abstract][Full Text] [Related]
7. Day/night differences in D1 but not D2 DA receptor protection from EEDQ denaturation in rats treated with continuous cocaine.
Burger LY; Martin-Iverson MT
Synapse; 1993 Jan; 13(1):20-9. PubMed ID: 8093985
[TBL] [Abstract][Full Text] [Related]
8. Differential recovery rates of rat D2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: a key to receptor regulatory mechanisms.
Norman AB; Battaglia G; Creese I
J Neurosci; 1987 May; 7(5):1484-91. PubMed ID: 2952771
[TBL] [Abstract][Full Text] [Related]
9. Effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on the prolactin suppression induced by a series of full and partial dopamine D2 receptor agonists in male rats.
Ekman A; Eriksson E
Naunyn Schmiedebergs Arch Pharmacol; 1992 Aug; 346(2):152-7. PubMed ID: 1360151
[TBL] [Abstract][Full Text] [Related]
10. EEDQ, a tool for ex vivo measurement of occupancy of D-1 and D-2 dopamine receptors.
Nowak G; Arnt J; Hyttel J
Eur J Pharmacol; 1988 Aug; 153(2-3):309-11. PubMed ID: 3053212
[TBL] [Abstract][Full Text] [Related]
11. Effect of aging on recovery of striatal dopamine receptors following N-ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline (EEDQ) blockade.
Henry JM; Roth GS
Life Sci; 1984 Aug; 35(8):899-904. PubMed ID: 6482680
[TBL] [Abstract][Full Text] [Related]
12. Chronic haloperidol affects striatal D2-dopamine receptor reappearance after irreversible receptor blockade.
Pich EM; Benfenati F; Farabegoli C; Fuxe K; Meller E; Aronsson M; Goldstein M; Agnati LF
Brain Res; 1987 Dec; 435(1-2):147-52. PubMed ID: 2962698
[TBL] [Abstract][Full Text] [Related]
13. In vivo labelling of pituitary dopamine D-2 receptors in the male rat using [3H]-raclopride.
Köhler C; Karlsson-Boethius G
J Neural Transm; 1989; 76(1):13-28. PubMed ID: 2523467
[TBL] [Abstract][Full Text] [Related]
14. Analysis of [3H]spiperone binding sites in the rat striatum and frontoparietal cortex by means of quantitative receptor autoradiography after inactivation of dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by sulpiride in the striatum.
Fuxe K; Meller E; Goldstein M; Benfenati F; Agnati LF
Neurosci Lett; 1986 Feb; 64(2):163-8. PubMed ID: 3960398
[TBL] [Abstract][Full Text] [Related]
15. N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain.
Xu SX; Hatada Y; Black LE; Creese I; Sibley DR
J Pharmacol Exp Ther; 1991 May; 257(2):608-15. PubMed ID: 1674530
[TBL] [Abstract][Full Text] [Related]
16. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors.
Hess EJ; Norman AB; Creese I
J Neurosci; 1988 Jul; 8(7):2361-70. PubMed ID: 2907912
[TBL] [Abstract][Full Text] [Related]
17. Alterations in the turnover rate of dopamine D1 but not D2 receptors in the adult rat neostriatum after a neonatal dopamine denervation.
Dewar KM; Paquet M; Reader TA
Neurochem Int; 1997 Jun; 30(6):613-21. PubMed ID: 9153003
[TBL] [Abstract][Full Text] [Related]
18. Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
Hamblin MW; Creese I
Life Sci; 1983 May; 32(19):2247-55. PubMed ID: 6133202
[TBL] [Abstract][Full Text] [Related]
19. Effect of chronic estradiol treatment on brain dopamine receptor reappearance after irreversible blockade: an autoradiographic study.
Morissette M; Lévesque D; Di Paolo T
Mol Pharmacol; 1992 Sep; 42(3):480-8. PubMed ID: 1357544
[TBL] [Abstract][Full Text] [Related]
20. Unilateral inactivation of dopamine receptors after intrastriatal injection of N-ethoxy-carbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): a novel rotational model to investigate dopamine receptor interactions.
Giorgi O; Biggio G
Pharmacol Biochem Behav; 1990 Apr; 35(4):877-84. PubMed ID: 1971721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
